■ Human conjunctival epithelial cells tolerated latanoprost plus benzalkonium chloride treatment administered via Optejet technology significantly better than the same compound administered via standard drops, according to a news release.

“Long term use of ophthalmic eye drops with preservatives is a significant clinical concern and therapeutic burden,” remarked Robert Weinreb, MD, chair of ophthalmology at the University of California, San Diego, and member of the Eyenovia scientific advisory board, in a news release. Per the study design, conjunctival epithelial cells were exposed to the drug by standard drop or Optejet, Eyenovia reported. Cell-based assays were then conducted to assess cell viability, cytotoxicity, apoptosis, reactive oxygen species generation, and ATP generation (metabolic activity).

“Due to the much smaller volume of drug and preservatives required with the Optejet device, the level of ocular surface damage due to preservative toxicity would be minimal,” said Beth Scott, OD, vice president of regulatory and medical affairs at Eyenovia, in a news release. “This study adds to the body of evidence supporting our breakthrough Optejet technology.”